Extended Data Fig. 7: Response in extra-medullary disease.
From: The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
A. PET scan at baseline and after 2 cycles of treatment. B. Computed tomographic scans of target lesions and spleen from a 19-year-old with relapsed KMT2Ar AML, previously treated with three prior lines of therapy including 2 allogeneic stem cell transplants and local radiation to the spleen and abdominal nodes, received revumenib at 276 mg PO q12h (Arm A), achieved CRh, MRD negative remission with resolution of extramedullary disease in abdominal nodes and spleen. AML, acute myeloid leukaemia; AP, anterior-posterior; CRh, complete remission with partial haematologic recovery; D, day; FDG, fluorodeoxyglucose; MRD, minimal or measurable residual disease; PET, positron emission tomography; PO, by mouth; q12h, every 12 h; SUV, standardized uptake value.
